OBX — Obsidian Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2130606 ·
Last close
$13.37
Market Cap
$825.90M
52W High
$49.97
52W Low
$12.16
ADV30
545,692
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -20,280,000 | -19,633,000 | 70,136,000 | 26,439,000 | 346,333,000 |
| Mar 2025 | 0 | — | -26,603,000 | -24,986,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-46,381,000
Investing CF
$21,502,000
Financing CF
$53,000
CapEx
$-56,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-315,568,000
Inventory
—
Receivables
—
ST Investments
$32,317,000
EBIT TTM
$-46,883,000
Pretax Income TTM
$-44,619,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -105,667,000 | -100,607,000 | 88,580,000 | 354,617,000 | -266,037,000 | -90,393,000 |
| Dec 2024 | 0 | -91,255,000 | -83,109,000 | 183,713,000 | 358,144,000 | -174,431,000 | -75,002,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.13
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMX | Immix Biopharma, Inc. | $820.56M | $11.47 | — |
| IVA | Inventiva S.A. | $833.86M | $3.53 | — |
| AVTX | Avalo Therapeutics, Inc. | $808.74M | $15.08 | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $845.42M | $1.90 | — |
| GERN | GERON CORP | $803.09M | $1.25 | — |
News headlines (Yahoo Finance, 1h cache)
Obsidian Therapeutics (OBX) Stock Dropped, So What Is Behind The Attention Now?
2026-08-13 01:11 · Yahoo
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
2026-08-06 13:48 · Yahoo
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls
2026-08-05 13:40 · Yahoo
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
2026-08-05 11:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.